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SUMMARY
Objective: To determine erythrocyte phenotyping in blood donors and patients with 
sickle cell anemia (SS) treated at Hemocentro of Alagoas and describe the frequency and 
factors associated with erythrocyte alloimmunization. Methods: Cross-sectional study 
with 102 SS patients and 100 blood donors. The following tests were performed: erythro-
cyte phenotyping, Direct and Indirect antiglobulin test, and detection of irregular anti-
bodies by panel of phenotyped red blood cells. Data were compared by Mann-Whitney, 
qui-square or Fisher’s exact tests. Factors associated with alloimmunization were studied 
by univariate and multiple logistic regression analysis. Results: The most frequent anti-
gens found in patients and blood donors were: c, e, M, s, JK(a). Significant differences 
were observed between the frequency of the phenotype of patients and donors in regard 
to antigens s, FY(a) and JK(b). Of 79 transfused patients, 10 presented positive Indirect 
Coombs. Thirteen alloantibodies were found, 7 of the Rh system, 2 of Kell and 4 were not 
identified. Factors associated with alloimmunization were the period of time between 
the last transfusion and the date of the test and more than 10 red blood cell transfu-
sions. Patients who received more than 10 transfusions were 16.39 (95% CI: 2.23-120.59) 
times more likely to be alloimmunized than patients with fewer transfusions. Conclu-
sion: The prevalence of alloimmunization in SS patients was 12.7%, with 70% of antibod-
ies belonging to the Rh and Kell systems. This study shows the importance of performing 
erythrocyte phenotyping in blood donors and receptors to decrease the risk of alloim-
munization.  
Keywords: Anemia, sickle cell; erythrocyte transfusion; donor selection; blood group 
antigens.
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INTRODUCTION
Transfusion therapy with packed red blood cells (PRBCs) 
is a common practice in the treatment and prevention of 
complications in sickle cell anemia (SS). Approximately 
50% of patients with SS receive transfusions of PRBCs 
at some stage of life and 5% to 10% of those enter the 
chronic transfusion program. The main objective of 
transfusion is to improve the capacity to transport oxy-
gen and blood flow in the microcirculation by decreasing 
the percentage of hemoglobin S (HbS) and increasing the 
hematocrit level, which should not exceed 30%, prevent-
ing clinically significant vaso-occlusive events1-8. 
Among the immune reactions to red blood cell trans-
fusions, alloimmunization to erythrocyte antigens is a 
relatively common complication and contributes sub-
stantially to increase the disease comorbidities. The al-
loimmunization, which is characterized by the presence 
of alloantibodies, occurs in approximately 5% to 25% of 
patients with sickle cell anemia undergoing a chronic 
transfusion regimen1,3,5,8-12. 
The study of erythrocyte phenotypes of blood groups 
in patients and blood donors provides a comparison of 
the frequency of the most immunogenic genes in each 
system, being important to decrease the risk of alloim-
munization, in addition to estimating the availability of 
compatible blood, especially in cases of previous delayed 
hemolytic transfusion reaction (DHTR)13. The use of 
blood products after the phenotyping of Rh (D, C, c, E, e) 
and Kell (K) systems reduces the cases of alloimmuniza-
tion and hemolytic transfusion reactions in patients with 
SS, compared to non-phenotyped red blood cell transfu-
sions14-16. 
In this context, this study aimed to study the preva-
lence of erythrocyte antigens in patients with SS in a 
sample of blood donors from Hemocentro de Alagoas 
(HEMOAL), in addition to detecting the rate of alloim-
munization in patients, assessing the alloantibodies in-
volved and factors associated with alloimmunization. 
METHODS
This is a cross-sectional study of patients with SS and 
blood donors seen at HEMOAL. This project was ap-
proved by the Research Ethics Committee of Universi-
dade Federal de São Paulo/Hospital São Paulo, protocol 
number 1416/08, and by the Ethics Committee of Uni-
versidade de Ciências da Saúde de Alagoas (UNCISAL) 
protocol # 1107. 
The study included patients with SS detected by he-
moglobin electrophoresis treated by the study researcher 
at HEMOAL in the period of December 2008 to April 
2010, who signed the Free and Informed Consent (FIC) 
form. Also included in the study were 100 HEMOAL 
blood donors who signed the FIC. Patients who had 
received transfusions in the last three months were ex-
cluded. We collected demographic data from patients and 
donors (age, sex and self-reported ethnicity). In addition, 
we collected patients’ characteristics regarding the number 
of transfusions and date of last transfusion through inter-
views, confirmed by the review of patients’ medical records. 
LABORATORY ASSESSMENT 
A 15 mL blood sample was collected from patients and 
donors – 5 mL in a tube containing EDTA and 10 mL in a 
dry tube, for the following laboratory assessments: blood 
type, hematocrit, hemoglobin, antibody screening by di-
rect and Indirect Coombs test and erythrocyte phenotyp-
ing. Erythrocyte phenotyping was performed for antigens 
A, B, D, C, c, E, e, K, M, N, S, s, Fy(a), Fy(b), JK(a) and 
JK(b). Samples that had irregular antibodies were submit-
ted to antibody identification by the erythrocyte antigen 
panel (RBC antigen panel).
Blood donors were phenotyped for antigens A, B, D, 
C, c, E, e, K, M, N, S, s, Fy(a), Fy(b), JK(a) and JK(b) and 
compared to those of patients with SS. 
The samples were tested to determine the direct and 
reverse blood typing using the tube technique. The Direct 
and Indirect Coombs test, red blood cell panel, autoanti-
body screening and phenotyping of other blood systems 
were performed by gel centrifugation technique using spe-
cific gel-test card (DiaMed Latino America AS, Brazil).
STATISTICAL ANALYSIS 
To calculate sample size, we used the estimated frequency 
of 60% or more for erythrocyte antigens more frequent-
ly found in our population, given an absolute accuracy 
of 10% and obtaining the number of 92 subjects in each 
group.
Numerical variables were expressed as median and 
minimum and maximum values  and compared using the 
Mann-Whitney test (non-normal distribution). Categori-
cal variables were expressed as numbers and percentages 
and compared using the Chi-square or Fisher’s exact test. 
For the analysis of factors associated with alloimmuniza-
tion, we used univariate and multiple logistic regression. 
Statistical significance level was set at p < 0.05. Statistical 
analysis was performed using SPSS for Win/v. 17.0, SPSS 
Inc., Chicago, IL. 
RESULTS
Of the 116 patients with SS who came for consultation at 
the Hemocentro of Alagoas in the study period, 14 pa-
tients did not sign the FIC and were not included in the 
study. Thus, 102 (87.9%) patients were studied. The mean 
age at study enrollment was 16.0 ± 12.3 years with a me-
dian of 11.5 (range: 0.7 to 48.6); 52 patients (51.0%) were 
males and 82 (80.4%) were non-Caucasian. 
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The present study included 100 blood donors, with a 
median age of 32.05 (range: 19.6 to 60.5) years; 69% were 
males and 79% self-reported being Caucasians.
Regarding the ABO blood groups, of the patients in-
cluded, 56 (54.9%) were type O, 37 (36.3%) were type A, 7 
(6.9%) were type B and 2 (2 , 0%) were type AB. Of the 102 
patients, 92 (90.2%) were Rh positive and 10 (9.8%) Rh 
negative. Blood donors had a similar distribution in rela-
tion to blood typing. 
Table 1 shows the frequencies of erythrocyte antigens 
of SS patients and blood donors. The most common an-
tigens in patients and donors were: c (93.1% vs. 83.0%), 
e (96.1% vs. 94.0%), M (82.4% vs. 82.0 %), s (92.2% vs. 
79.0%), JK(a) (88.2% vs. 82.0%). Statistically significant 
differences were observed between patients and donors re-
garding the frequency of antigen s, FY(b) and JK(b). 
Of the 102 patients, 79 (77.5%) received at least one 
red blood cell transfusion prior to study enrollment and 
39 (38.2%) received one to five transfusions, 10 (9.8%) re-
ceived six to ten and 30 (29.4%) received more than ten 
transfusions. 
The median age of patients who received at least one 
red blood cell transfusion was 13.0  years (range: 1.4 to 
48.6), whereas nontransfused patients’ median age was 
7  years (range: 0.7 to 40.1), p  =  0.016. The proportion 
of males and females was similar in transfused patients 
(48.1% vs. 51.4%, p = 0.281). 
Patients had similar hemoglobin and hematocrit levels 
at the time of enrollment. The median hemoglobin level was 
7.4 g/dL (range: 5.0 to 11.2) and 7.7 g/dL (range: 6.1 to 10.5), 
p = 0.226 and hematocrit was 21.9% (range: 13.4 to 33.6%) 
and 22.5% (range: 17.7 to 29.5%), p = 0.225, respectively, 
in transfused and nontransfused patients. 
Of the 79 previously transfused patients, 10 (12.7%) 
had a positive Indirect Coombs test. Thirteen antibod-
ies were detected, of which 7 belonged to the Rh system 
(1 anti C, 1 anti c, 2 anti D, and 3 anti E), two belonged to 
the Kell system (one anti Kell, one anti Kpa) and four were 
not identified.  
Alloimmunized patients tended to be older at the 
moment of study enrollment with a median age of 24.6 
(range: 1.7 to 47.6) years among alloimmunized individu-
als and 11.5 (range: 1.36 to 48.6) years among those who 
had a negative Indirect Coombs test (Mann-Whitney 
test, p = 0.059). The frequency of alloimmunization was 
similar in the group of children and adolescents, when 
compared with those older than 19 years (40% vs. 60%, 
Fisher’s exact test, p = 0.179). Likewise, male and female 
individuals had similar rates of alloimmunization (50% 
vs. 50%, Fisher’s exact test, p = 1.000). Regarding ethnic-
ity, 8 (12.7%) non-Caucasian and 2 (12.5%) Caucasian 
individuals had positive Indirect Coombs test (Fisher’s 
exact test, p = 1.000). 
One alloimmunized patient had received three trans-
fusions of red blood cells, another had received five 
transfusions and eight patients had received more than 
10 transfusions. Patients who had received more than 10 
transfusions had a higher frequency of alloimmunization, 
when compared to those that had received fewer than 
10 (80% vs. 20%, Fisher’s exact test, p = 0.005).  







Ag D 92 (90.2%) 89 (89%) 0.781
Ag C 55 (53.9%) 58 (58%) 0.559
Ag CW 0 (0%) 2 (2%) 0.244 *
Ag c 95 (93.1%) 83 (83%) 0.026
Ag E 29 (28.4%) 27 (27%) 0.820
Ag e 98 (96.1%) 94 (94%) 0.535
Ag K 8 (7.8%) 4 (4%) 0.373*
Ag M 84 (82.4%) 82 (82%) 0.948
Ag N 64 (62.7%) 63 (63%) 0.970
Ag S 44 (43.1%) 44 (44%) 0.902
Ag s 94 (92.2%) 79 (79%) 0.008
Ag Fy(a) 60 (58.8%) 53 (53%) 0.405
Ag Fy(b) 47 (46.1%) 66 (66%) 0.004
Ag JK(a) 90 (88.2%) 82 (82%) 0.213
Ag JK(b) 51 (50%) 72 (72%) 0.001
p-value, chi-square; * Fisher’s exact test.
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The interval between the last transfusion and date of 
the erythrocyte antibody screening was similar in the al-
loimmunized and non-alloimmunized groups. This period 
was 1.2 (range: 0.3 to 13.5) years in alloimmunized and 
1.3 (range: 0.3 to 11.4) years in non-alloimmunized indi-
viduals (Mann-Whitney test, p = 0.871 ). 
The levels of hemoglobin and hematocrit were similar 
in patients with positive or negative Indirect Coombs. The 
median hemoglobin level was 7.1 g/dL (range: 6.6 to 11.2) 
and 7.4 g/dL (range: 5.0 to 10.7), respectively, in alloim-
munized and non-alloimmunized individuals, through 
Mann-Whitney test, p  =  0.929. The median level of he-
matocrit in patients with positive Coombs was 20.6 g/dL 
(range: 18.7 to 33.6)  and 22.0 g/dL (range: 13.4 to 31.9)  in 
the other group (Mann-Whitney test, p = 0.929).
To study the factors associated with alloimmunization 
in patients with SS, we initially performed the univariate 
logistic regression, including possible associated factors 
described in the literature (Table 2). Variables such as pa-
tient age, interval between transfusions and more than 10 
transfusions of red blood cells, which showed statistical 
significance < 0.20 in the univariate analysis, were includ-
ed in the multivariate model.   
alloantibodies make it difficult to obtain compatible blood 
and can cause acute or delayed hemolytic transfusion reac-
tions, increasing morbidity. 
In the present study, we observed that donors were 
mostly males (69%) and self-reported being Caucasians 
(79%), as described in the study by Sakhalkar et al.17. 
Two studies reported differences in the frequency 
of antigen in blood donors and SS patients detected 
by erythrocyte phenotyping. The study by Moreira Jr. 
et al.3, showed significant difference in the C antigen 
frequency and the one by Matsuura18 showed difference 
in the frequency of D, Fy(a), Fy(b), S and s antigens. 
The comparative analysis of erythrocyte phenotypes in 
patients with sickle cell disease and blood donors de-
tected differences did not influence erythrocyte alloim-
munization, as no alloantibodies were detected against 
these antigens. Therefore, these data show that they are 
similar in the main phenotypes of blood group systems.
When evaluating the antibodies present in alloim-
munized patients, we found 13 antibodies, and only 
three patients had more than one alloantibody. The al-
loimmunization rate was 12.7%, similar to that found 
by Moreira Jr et al.3 in a study carried out in São Paulo 
(12.9%) and by Murao and Viana19 in Minas Gerais 
(9.9%). 
In the present study, of 13 the antibodies found, sev-
en belonged to the Rh system, two to the Kell system 
and four were not identified, without any agreement 
with the phenotypic difference of donors for antigens 
s, FY(b) and JK(B). Most alloantibodies found belonged 
to the RH system, similar to what was observed in other 
studies showing that Rh system antigens are among the 
most immunogenic ones. Moreover, alloimmunization 
in SS depends on other factors such as immune re-
sponse, the number and frequency of transfusions, anti-
gen immunogenicity, the presence of HLA-B35 antigen 
and receiver’s gender5,19-21.  
The demographic variables studied herein were not 
associated with alloimmunization (Table 2). It was ob-
served that of 102 patients with SS, 79 (77.5%) received 
transfusions and 10 (12.6%) were alloimmunized, of 
which four were females and six were males. The allo-
immunization rate is generally higher in women due to 
pregnancy and abortion history, which did not happen 
in this study, probably due to the predominance of chil-
dren in the sample17,19,22,23. 
In the present investigation, alloimmunization 
predominated in patients with more than 10 transfu-
sions, similar to the study by Sakhalkar et al.17, who ob-
served that most patients developed alloantibodies after 
12 transfusions and that by Natukunda et al.8, in which 
80.7% of alloimmunized patients had received more 
than 10 transfusions. 
The final model of multiple logistic regression showed 
that: each additional year between the last transfusion 
and erythrocyte antibody screening increased by 36.9% 
the chance that the patient is alloimmunized (OR: 1.369, 
95%  CI: 1.059-1.771, p  =  0.017) and patients who had 
received more than 10 red blood cell transfusions had a 
16-fold higher chance of presenting alloimmunization 
(OR: 16.390, 95% CI: 2.228-120.586, p = 0.006) when com-
pared to patients with fewer than 10 transfusions.  
DISCUSSION
The erythrocyte immunophenotyping in patients with SS 
is important to prevent one of the major complications of 
transfusion therapy, as the presence of autoantibodies and 
Variables OR 95% CI p
Age (years) 1.062 1.008-1.118 0.013
Male sex 1.091 0.290-4.111 0.898
Caucasian 0.982 0.187-5.149 0.983
More than 10 
transfusions
8.545 1.674-43.620 0.010
Interval between the last 
transfusion and antibody 
screening (years)
1.219 0.992-1.497 0.059
Table 2 – Univariate logistic regression for factors associated 
with alloimmunization in patients with sickle cell anemia
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In the present study, the presence of several uniden-
tified antibodies draws attention to limitations of the 
method used, in addition to the existence of other anti-
bodies that have yet to be screened. In some cases, due to 
particular characteristics or very low titers, the alloanti-
body is only detected by using special techniques such as 
prolonged incubation, the use of enzyme-treated eryth-
rocytes or with low ionic concentration mean5,19,24.  
Our results are similar to those obtained in a study 
carried out in Saudi Arabia with retrospective analysis 
of clinical and transfusion history of 350 patients aged 
2 to 75 years, who had received at least one transfusion. 
These authors identified alloimmunization in 48 (13.7%) 
patients and the alloantibodies detected were: anti-E 
(18.8%), unspecified (12.5%), inconclusive (12.5%), anti-
K (10.4%) and anti-c (6.3%) and most cases with multiple 
antibodies. We concluded, as Bashawri20, that the preva-
lence of alloimmunization and its consequences are im-
portant for clinical management and laboratory practices 
of patients with SS. 
The rate of alloimmunization found in this study 
was 12.7% and 30% of the antibodies were not identi-
fied. In the study by Matsuura18, of 72 patients with 
SS, previously transfused, the presence of irregular 
anti-erythrocyte antibodies was detected in 13 (18%) 
cases. Fourteen alloantibodies were detected, being 
5 (32.7%) of the Rh system, 4 (28.6%) of Kell, 1 (7.1%) 
of the MNSs system, 1 (7.1%) of the Lewis system and 
3 (21.5%) were not identified.   
Screening for autoantibodies by DC was negative in 
all patients in the present study, whereas in the study 
by Matsuura18 in Manaus, 6 (8.3%) tests were positive. 
This study showed a statistically significant difference 
(p < 0.05) between patients and blood donors regarding 
the frequency of antigen D, S, Fy(a), Fy(b) and s, with the 
latter two antigens being also significant in the present 
study, in addition to JK(b). Therefore, the rate of alloim-
munization and antigens involved in this research and in 
the study by Matsuura18 showed concordant results. 
Erythrocyte phenotyping of patients and donors 
showed a statistical difference for the Ag c, reinforcing 
the importance of using blood phenotyped for the Rh 
system. We also verified a statistical difference of anti-
gen s, Fy(b) and JK(b), which are less immunogenic than 
the Rh system, but it reflects the importance of the ex-
tended phenotyping of the MNSs, Kidd and Duffy blood 
systems to prevent alloimmunization in patients with 
SS, in agreement with Araújo et al.25, who recommend 
expanding the screening of erythrocyte antigens when 
indicating red blood cell transfusion in multitransfused 
patients. The study by Godfrey16 showed a decrease in the 
formation of autoantibodies and alloantibodies after in-
troduction of C, E and K antigen phenotyping.  
The final model of multiple logistic regression showed 
that for every additional year in the interval between the 
last transfusion and erythrocyte antibody screening, 
there was a 36.9% increase in the chance for the patient 
to be alloimmunized. Similarly, a retrospective multi-
center study carried out in the United States emphasized 
that the time interval between transfusion and antibody 
detection was associated with antibody specificity and 
its early detection could reduce the risk of hemolytic 
transfusion reaction23. Fabron Jr.5 observed that within 
10 months, 21% of previously documented alloantibod-
ies had disappeared.
Patients who received more than 10 red blood cell 
transfusions had a 16-fold higher chance of being al-
loimmunized, compared to patients with fewer than 
10 transfusions. It was observed that 80% of alloim-
munized individuals had received over 10 units of red 
blood cells; as in the study by Fabron Jr.5, most alloim-
munized patients (61.5%) had previously received more 
than 10 units of PRBCs. According to Moreira Jr et al.3, 
the estimated risk of alloimmunization per unit of PRBCs 
transfused to Brazilian individuals with SS is approxi-
mately 1.15%. 
In conclusion, phenotyping of erythrocyte donors 
and patients showed the importance of identifying the 
differences in phenotypes between donors and recipients, 
in order to avoid alloimmunization, a major complica-
tion of transfusion therapy. The prevalence of alloim-
munization in patients was 12.7%, with 70% being from 
antibodies belonging to the Rh and Kell blood groups. 
Factors associated with erythrocyte alloimmunization in 
patients with sickle cell disease were the fact of receiving 
more than 10 red blood cell transfusions and longer time 
after the transfusion of red blood cells. 
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